MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients.
Paolo CameliElena PordonMiriana d'AlessandroMaria Laura MarziLucrezia GalassoCesare BiuzziLaura BergantiniElena BargagliSabino ScollettaFederico FranchiPublished in: Biomedicines (2023)
Our data sustain the potential of serum MR-proADM as a reliable prognostic biomarker of hospitalized COVID-19 patients and confirms the utility of the three markers in the management and risk stratification of hospitalized patients. The markers are collected mini-invasively and are quick to analyze and cost-effective.